GlassScriptPhysician profile
Thomas W Harper
NPI 1346440583
$3,220.04
in general payments reported to CMS, 2019-2025
22 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $174 · 2021: $228 · 2022: $280 · 2023: $876 · 2024: $878 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.25 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $534.87 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $525.00 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $492.57 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $322.34 | 2023-2025 | Syfovre |
| Alimera Sciences, INC. | $266.70 | 2019-2024 | Yutiq, Iluvien |
| Abbvie INC. | $218.32 | 2022-2025 | |
| Allergan, INC. | $126.95 | 2019-2022 | |
| Rxsight INC | $110.37 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $98.53 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $83.10 | 2021 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $61.88 | 2023-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Biogen, INC. | $57.69 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $54.62 | 2022-2024 | Visudyne, Xipere |
| Genentech, INC. | $49.23 | 2022-2023 | Vabysmo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $43.09 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $26.08 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $17.98 | 2019 | |
| Coopervision INC. | $17.48 | 2022 | |
| Ocular Therapeutix, INC. | $12.19 | 2022 | |
| Eyevance Pharmaceuticals LLC | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.